证券代码：688581 证券简称：安杰思 公告编号：2025-038 杭州安杰思医学科技股份有限公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 杭州安杰思医学科技股份有限公司（以下简称"公司"）第三届董事会第二 次会议于 2025 年 06 月 17 日以现场结合通讯的方式在公司九楼会议室召开。本 次会议通知及相关材料已于 2025 年 6 月 6日以专人送达方式通知公司全体董事， 与会的各位董事已知悉与所议事项相关的必要信息。会议由董事长张承主持， 会议应到董事 5 人，实际出席董事 5 人，公司部分高级管理人员列席了本次会 议。本次会议的召集和召开程序符合《公司法》和《公司章程》的有关规定。 二、 董事会会议审议情况 （一）审议通过了《关于向 2025 年限制性股票激励计划激励对象授予限制 性股票的议案》 董事会认为：根据《上市公司股权激励管理办法》《上海证券交易所科创板 股票上市规则》《科创板上市公司自律监管指南第 4 号--股权激励信息披露》等 有关法 ...

杭州安杰思医学科技股份有限公司 特此公告。 杭州安杰思医学科技股份有限公司董事会 证券代码：688581 证券简称：安杰思 公告编号：2025-035 关于变更保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安杰思医学科技股份有限公司（以下简称"公司"）首次公开发行股票 并在科创板上市的保荐机构为中信证券股份有限公司，(以下简称"中信证券" 或"保荐机构")，原委派徐峰先生、王鹏先生为公司首次公开发行股票并在科 创板上市的保荐代表人，负责保荐工作及持续督导工作，持续督导期 2023 年 5 月 19 日至 2026 年 12 月 31 日。 近日，公司收到《中信证券股份有限公司关于更换杭州安杰思医学科技股份 有限公司持续督导保荐代表人的函》，原保荐代表人王鹏先生因工作安排原因， 无法继续从事对公司的持续督导工作。为保证持续督导工作的有序进行，中信证 券现委派保荐代表人余启东先生(简历详见附件)接替王鹏先生继续行持续督导 工作。本次保荐代表人更换后，公司首次公开发行股票并在科创板上市项目持续 督导保荐代 ...

Group 1 - The company, Hangzhou Anjisi Medical Technology Co., Ltd., has announced a change in its sponsoring representatives for its initial public offering (IPO) on the Sci-Tech Innovation Board [1][2] - The original sponsoring representative, Mr. Wang Peng, is unable to continue due to work arrangements, and Mr. Yu Qidong has been appointed as his replacement [1][2] - The new sponsoring representatives for the company's IPO project will be Mr. Xu Feng and Mr. Yu Qidong, ensuring the continuity of the ongoing supervision work [1][2] Group 2 - The change in sponsoring representatives will not affect the conclusions of the documents previously issued by the sponsoring institution and representatives [2] - The board of directors expresses gratitude for Mr. Wang Peng's contributions during the IPO and ongoing supervision period [2] - Mr. Yu Qidong, the new representative, has a good professional record and has participated in various projects, including the IPO project of Anjisi [2]

证券代码：688581 证券简称：安杰思 公告编号：2025-034 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 杭州安杰思医学科技股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开了第二届董事会第十九次会议以及第二届监事会第十五次会议，审议通过 了《关于<公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等相 关议案，并于 2025 年 4 月 23 日在上海证券交易所网站（www.sse.com.cn）上披 露了相关公告。 根据《上市公司信息披露管理办法》《上市公司股权激励管理办法》《上海证 券交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权 激励信息披露》等法律、法规及规范性文件的要求，公司对 2025 年限制性股票 激励计划（以下简称"本激励计划"）采取了充分必要的保密措施，同时对本激 励计划内幕信息知情人进行了登记管理。并对本激励计划内幕信息知情人在本激 励计划公告前六个月买卖公司股票情况进行查询，实际查询期间为 2024 年 10 月 21 日至 2 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjies Medical Technology Co., Ltd., which has a closing price of 64.97 yuan and a rolling PE ratio of 17.72, marking a new low in 12 days [1] - The company operates in the medical device industry, which has an average PE ratio of 51.00 and a median of 37.03, placing Anjies at the 41st position in the industry ranking [1][2] - As of the first quarter of 2025, 11 institutions hold shares in Anjies, with a total of 17.73 million shares valued at 1.26 billion yuan [1] Group 2 - Anjies specializes in the research, production, and sales of endoscopic minimally invasive diagnostic and therapeutic devices, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - The company has received seven significant government honors, including recognition as a "Zhejiang Provincial Enterprise Technology Center" and "Zhejiang Provincial High-Growth Biopharmaceutical Enterprise" [1] - In the latest financial report for the first quarter of 2025, Anjies reported revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.25 million yuan, reflecting a year-on-year growth of 6.57% with a gross margin of 70.68% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjisi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive endoscopic diagnostic and therapeutic instruments [1][2] - As of May 29, Anjisi's closing stock price was 64.92 yuan, reflecting a 1.41% increase, with a rolling price-to-earnings (PE) ratio of 17.71 times and a total market capitalization of 5.257 billion yuan [1] - The average PE ratio for the medical device industry is 49.64 times, with a median of 36.36 times, positioning Anjisi at the 41st rank within the industry [1][2] Group 2 - As of the first quarter of 2025, 11 institutions held shares in Anjisi, including 6 funds and 5 other entities, with a total holding of 17.7325 million shares valued at 1.26 billion yuan [1] - Anjisi's main business involves the research, production, and sales of endoscopic minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - In the latest quarterly report, Anjisi reported a revenue of 129 million yuan, representing a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, with a year-on-year growth of 6.57%, and a gross profit margin of 70.68% [1]

Meeting Details - The first meeting of the third Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held, with all three supervisors present, confirming the legality and validity of the meeting [1][2] - The meeting was convened following the election of the non-employee representative members at the annual shareholders' meeting [1] Resolutions Passed - The Supervisory Board approved the election of Mr. Shi Baoming as the chairman of the third Supervisory Board, with his term starting from the date of this meeting until the end of the current board's term [1][2] - The voting results were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [2]

Core Viewpoint - The legal opinion provided by Beijing Deheng (Hangzhou) Law Firm confirms the legality of the 2024 annual general meeting of Hangzhou Anjisi Medical Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1][3][12] Group 1: Meeting Procedures - The annual general meeting is scheduled for May 16, 2025, with proper notification published on the Shanghai Stock Exchange and other designated media [3][4] - The meeting will utilize a combination of on-site and online voting methods, with specific timeframes for both [4][5] - The meeting's procedures for convening and conducting are deemed compliant with the Company Law and other relevant regulations [4][5] Group 2: Attendance and Voting - The record date for shareholder attendance is set for May 12, 2025, with 48 shareholders and their proxies representing 57,830,094 shares, accounting for 71.7701% of the total voting shares [4][5] - The voting results indicate a high level of agreement among shareholders, with significant support from minority investors [6][7][8] Group 3: Voting Results - A total of 18 agenda items were voted on, with the majority receiving overwhelming support, including votes from minority shareholders [5][6][9] - Specific resolutions, such as the election of directors and supervisors, received substantial approval, reflecting strong shareholder confidence [10][11] Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendance, and voting procedures, are in accordance with the Company Law and the company's articles of association, rendering the resolutions valid [12]

Core Viewpoint - The shareholders' meeting of Hangzhou Anjisi Medical Technology Co., Ltd. was held on May 16, 2025, with all proposed resolutions approved by the shareholders [1][6]. Meeting Details - The meeting took place at Room 302, 3rd Floor, No. 389 Xingzhong Road, Linping District, Hangzhou [1]. - A total of 48 ordinary shareholders attended the meeting, holding 57,830,094 voting rights, which accounted for 71.77% of the company's total voting rights [1]. Voting Results - All non-cumulative voting proposals were approved, with the following voting results: - Proposal 1: 57,694,589 votes in favor (99.77%), 121,105 votes against (0.21%), and 14,400 abstentions (0.03%) [2]. - Proposal 2: 57,691,389 votes in favor (99.76%), 124,305 votes against (0.21%), and 14,400 abstentions (0.03%) [2]. - Proposal 3: 57,692,589 votes in favor (99.76%), 137,505 votes against (0.24%), and no abstentions [3]. Election of Directors - The election of directors was conducted with the following results: - Zhang Cheng was elected with 55,363,070 votes (95.73%) [3]. - Zhang Qianyi was elected with 55,363,071 votes (95.73%) [3]. - Shen Menghui was elected with 55,392,711 votes (95.79%) [4]. - Feng Yang was elected with 55,392,710 votes (95.79%) [4]. Legal Compliance - The meeting and voting procedures complied with the Company Law and the company's articles of association, ensuring the legality and validity of the resolutions passed [6].

Core Viewpoint - The company has completed the election of its third board of directors and supervisory board, along with the appointment of senior management personnel, marking a significant governance transition [1][3]. Board of Directors Election - The third board of directors consists of two non-independent directors, two independent directors, and one employee representative director, with a term of three years starting from the approval date of the 2024 annual general meeting [1][2]. - Zhang Cheng was elected as the chairman of the board, and various specialized committees were formed, including the audit committee, nomination committee, compensation and assessment committee, and strategic committee [2]. Supervisory Board Election - The third supervisory board includes two non-employee representative supervisors and one employee representative supervisor, with a term of three years starting from the approval date of the 2024 annual general meeting [3][4]. - Shi Baoming was elected as the chairman of the supervisory board [4]. Senior Management Appointments - The company appointed a new general manager, deputy general managers, a financial director, and a board secretary, all of whom meet the qualifications required by relevant laws and regulations [4][5]. - The board secretary, Zhang Qinhua, holds the necessary qualifications to perform his duties effectively [4][5]. Securities Affairs Representative Appointment - Du Xinyu was appointed as the securities affairs representative, assisting the board secretary with daily securities matters [5][10]. Departure of Previous Board Members - Following the completion of the election, three previous board members, including Sheng Yueyuan and independent directors Wu Jianhai and Xia Lianan, have completed their terms and are no longer serving on the board [6][7].